Volume | 10,870 |
|
|||||
News | - | ||||||
Day High | 1.85 | Low High |
|||||
Day Low | 1.63 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sonnet BioTherapeutics Holdings Inc | SONN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.85 | 1.63 | 1.85 | 1.65 | 1.72 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
228 | 10,870 | $ 1.73 | $ 18,854 | - | 1.08 - 26.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:33:27 | 76 | $ 1.66 | USD |
Sonnet BioTherapeutics Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.06M | 3.07M | - | 148k | -18.83M | -6.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sonnet BioTherapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SONN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.67 | 2.00 | 1.63 | 1.85 | 32,562 | -0.02 | -1.20% |
1 Month | 1.82 | 2.00 | 1.49 | 1.70 | 29,782 | -0.17 | -9.34% |
3 Months | 2.15 | 2.23 | 1.49 | 1.82 | 24,490 | -0.50 | -23.26% |
6 Months | 1.58 | 2.3399 | 1.30 | 1.89 | 68,353 | 0.07 | 4.43% |
1 Year | 13.4618 | 26.40 | 1.08 | 11.57 | 654,339 | -11.81 | -87.74% |
3 Years | 511.28 | 637.56 | 1.08 | 139.54 | 2,851,165 | -509.63 | -99.68% |
5 Years | 1,915.76 | 4,989.60 | 1.08 | 329.62 | 2,527,914 | -1,914.11 | -99.91% |
Sonnet BioTherapeutics Description
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |